What is the primary value proposition of Estasharah?

Based on Slide 6, the company focuses on four pillars: High Responsiveness, Remoteness Accessibility, All Medical Specializations, and consultations that are Customized to Medical History. By integrating with social platforms like Messenger, they aim to provide immediate medical advice without the need for physical travel, leveraging a bot-assisted intake process to ensure doctors have relevant data before responding.

How does the company generate revenue?

According to Slide 7, the revenue model is two-fold. The primary source is a commission on consultations, which ranges from 40% to 60% of the fee paid by the patient. The secondary source is advertising, specifically described as 'Online Marketing for Doctors on Medicobot,' allowing practitioners to pay for visibility within the platform's ecosystem.

What is the user experience for a patient?

The deck outlines a five-step process: entering via a social app (Slide 2), filling out a medical history (Slide 3), selecting a consultation package (Slide 4), paying the fee, and receiving an answer from a doctor (Slide 5). The interface shown is in Arabic, indicating a primary focus on the Middle East and North Africa (MENA) market, specifically Egypt, given the L.E (Egyptian Pound) currency.

Who are the key competitors mentioned in the deck?

Slide 6 explicitly shows the logos for Altibbi and Cura. These are established players in the MENA telehealth space. Estasharah attempts to differentiate itself through its high responsiveness and the depth of medical history customization, though the deck does not provide a feature-by-feature comparison matrix to prove these advantages.

What critical information is missing from this pitch deck?

The deck is missing several fundamental investment slides. There is no 'Ask' slide detailing how much capital is being raised or how it will be used. Furthermore, it lacks a 'Problem' slide to quantify the pain point, a 'Market Size' (TAM/SAM/SOM) slide, 'Traction' metrics (user growth, revenue to date), and 'Financial Projections' for future years.

Estasharah Pitch Deck (2018): 23-Slide Breakdown

See all 23 slides of the Estasharah pitch deck — a 2018 deck — with a slide-by-slide teardown of what the deck does well and where it falls short.

Estasharah is a telehealth platform designed to connect patients with doctors via a mobile interface, specifically utilizing Facebook Messenger as a primary entry point. The deck, dating from late 2018, leans heavily on product screenshots to demonstrate the user journey, from initial medical history intake to payment and doctor response. While the deck provides a clear view of the 'Medicobot' interface and a dual-revenue stream consisting of high-margin commissions (40-60%) and advertising, it lacks critical investor data. There is no mention of market size, current traction, financial proje…

Key takeaways

The platform utilizes Facebook Messenger for 'Instant Access,' suggesting a low-friction user acquisition strategy (Slide 2).
The user onboarding process includes a detailed digital medical history form to customize consultations (Slide 3).
Consultation pricing is tiered, with a standard option at L.E 25 and a 'Plus' option at L.E 39 (Slide 4).
The doctor-facing interface allows for structured responses, including fields for medication, dosage, and required scans or tests (Slide 5).
Estasharah identifies Altibbi and Vezeeta (indicated by the Cura logo) as primary competitors in the regional market (Slide 6).
The business model relies on a significant commission rate of 40% to 60% on consultations (Slide 7).
A secondary revenue stream is planned through 'Online Marketing for Doctors' via ads on the Medicobot platform (Slide 7).
The team is fully staffed across technical roles, including Back-End, Front-End, and Android developers, alongside a Social Media Specialist (Slide 8).

Estasharah Pitch Deck Analysis

The Estasharah pitch deck from November 2018 serves primarily as a product walkthrough for a telehealth solution focused on the Egyptian market. While the visual identity is consistent, the deck functions more as a functional specification or a sales presentation than a traditional venture capital pitch. It lacks the macro-economic data and traction metrics usually required to secure institutional funding, focusing instead on the mechanics of the 'Medicobot' interface.

Slide 1: Title Slide

The title slide features the Estasharah logo, which incorporates a heart shape and a chat bubble icon, signaling the intersection of healthcare and communication. The Arabic tagline 'دكتورك بين يديك' translates to 'Your doctor in your hands,' reinforcing the mobile-first nature of the service. The design is clean, using a palette of blue and green, which are standard colors for the healthcare technology sector.

Slide 2: Instant Access

This slide highlights the entry point for users. Rather than requiring a standalone app download immediately, Estasharah points to Facebook Messenger as a primary channel for 'Instant Access.' This is a strategic choice for the 2018 Egyptian market, where Facebook usage was high, and reducing friction for first-time users is critical for adoption. The slide uses a smartphone mockup to show the Messenger icon within a 'Social Apps' folder.

Slide 3: Medical History Intake

Slide 3 demonstrates the second step of the user journey: 'Filling the basic medical history.' The screenshot shows an Arabic form within the 'Medicobot' interface. Fields appear to include location (Egypt, Giza, Dokki), date of birth, and gender. This step is vital for telehealth platforms to ensure that the consulting physician has context before the interaction begins, potentially improving the quality of the advice given.

Slide 4: Monetization and Tiers

This slide, titled '5. Paying for the consultation,' reveals the pricing strategy. Two tiers are shown: a standard consultation for L.E 25 (approximately $1.40 USD in 2018) and a 'Plus' consultation for L.E 39 (approximately $2.20 USD). The 'Plus' option promises a faster and more detailed response. The presence of a '35% discount' badge on the Plus tier suggests an active promotional strategy to upsell users to the higher-margin service.

Slide 5: The Doctor's Response

Slide 5 shows the interface from the physician's perspective or the resulting output for the patient. Titled '3. Answering Patient,' the screen includes a text area for the doctor's advice and structured fields for 'Medication Name,' 'Dosage,' 'Scan Name,' and 'Test Name.' This structured data approach is superior to simple text chat, as it allows for better record-keeping and potential integration with pharmacies or diagnostic labs in the future.

Slide 6: Competitive Positioning

The company uses a four-circle Venn-style diagram to position itself. The core attributes claimed are High Responsive, Remoteness Accessibility, All Medical Specializations, and Customized to Medical History. To the right, the logos of Altibbi and Cura are displayed. While it identifies these competitors, the slide fails to explain why Estasharah is better than these well-funded incumbents, other than the four general adjectives provided.

Slide 7: Business Model

The business model is presented through two overlapping circles. The primary revenue driver is 'Commissions' at a rate of 40% - 60% on consultations. This is an exceptionally high commission rate for a marketplace, which usually ranges between 15% and 30%. The second revenue stream is 'Ads,' specifically 'Online Marketing for Doctors on Medicobot.' This suggests a B2B play where doctors pay for lead generation or featured placement within the bot.

Slide 8: Team Composition

The final slide in this selection introduces the team. It is a large team for an early-stage startup, featuring eight individuals. The leadership includes Eslam M. Youssef (CEO), Ahmed Said (CMO), and Ahmed Ibrahim (CTO). The technical side is well-represented with a Back-End Developer, Front-End Developer, and Android Developer. The inclusion of a Social Media Specialist and a Product Manager suggests the company was focused on both product iteration and user acquisition via social channels.

What Estasharah Does Well

The deck excels at explaining the product flow. By using actual screenshots of the 'Medicobot,' the founders remove any ambiguity about how the service works. The integration with Facebook Messenger is a smart 'Trojan Horse' strategy for market entry in regions with high social media penetration but lower app-store engagement. Furthermore, the business model slide is refreshingly direct about their take rate, even if that rate is aggressively high.

What is Missing from the Deck

As a fundraising tool, this deck is incomplete. The most glaring omission is the lack of a 'Problem' slide; we are shown a solution without being told the scale of the inefficiency it solves. There is no data on the Egyptian healthcare market, the number of doctors available, or the target demographic's spending habits. Most importantly, there is no traction slide. Investors need to know how many consultations have been completed, the customer acquisition cost (CAC), and the lifetime value (LTV) of a user. Finally, the absence of a 'Funding Ask' means the deck fails to communicate what the founders actually want from the reader.

Founder Takeaways

Show, Don't Just Tell: Using screenshots to walk through a user journey is highly effective for technical products. It proves the product exists and is functional. · Address the Incumbents: Simply listing competitors isn't enough. Founders should use a comparison table to show specific feature advantages or price-point superiorities. · Be Realistic with Commissions: A 60% commission is difficult to sustain as you scale, as it incentivizes service providers (doctors) to move off-platform. Founders should justify such high rates with high-value services. · Include the 'Why Now': A pitch deck needs to explain why this is the right moment for this specific solution. Estasharah missed an opportunity to discuss the digital transformation of the MENA region. · Don't Forget the Ask: Every pitch deck must end with a clear request for capital, including the amount, the instrument (SAFE, Equity), and the milestones that capital will achieve.

Frequently asked questions

What is the primary value proposition of Estasharah?: Based on Slide 6, the company focuses on four pillars: High Responsiveness, Remoteness Accessibility, All Medical Specializations, and consultations that are Customized to Medical History. By integrating with social platforms like Messenger, they aim to provide immediate medical advice without the need for physical travel, leveraging a bot-assisted intake process to ensure doctors have relevant data before responding.
How does the company generate revenue?: According to Slide 7, the revenue model is two-fold. The primary source is a commission on consultations, which ranges from 40% to 60% of the fee paid by the patient. The secondary source is advertising, specifically described as 'Online Marketing for Doctors on Medicobot,' allowing practitioners to pay for visibility within the platform's ecosystem.
What is the user experience for a patient?: The deck outlines a five-step process: entering via a social app (Slide 2), filling out a medical history (Slide 3), selecting a consultation package (Slide 4), paying the fee, and receiving an answer from a doctor (Slide 5). The interface shown is in Arabic, indicating a primary focus on the Middle East and North Africa (MENA) market, specifically Egypt, given the L.E (Egyptian Pound) currency.
Who are the key competitors mentioned in the deck?: Slide 6 explicitly shows the logos for Altibbi and Cura. These are established players in the MENA telehealth space. Estasharah attempts to differentiate itself through its high responsiveness and the depth of medical history customization, though the deck does not provide a feature-by-feature comparison matrix to prove these advantages.
What critical information is missing from this pitch deck?: The deck is missing several fundamental investment slides. There is no 'Ask' slide detailing how much capital is being raised or how it will be used. Furthermore, it lacks a 'Problem' slide to quantify the pain point, a 'Market Size' (TAM/SAM/SOM) slide, 'Traction' metrics (user growth, revenue to date), and 'Financial Projections' for future years.

Cover slide of the Estasharah pitch deck — 2018 — Estasharah pitch deck, slide 1 (2018)

Estasharah pitch deck: the facts

Company: Estasharah
Year: 2018
Slides: 23
Sector: Telehealth / Healthtech
Deck type: Product / Pitch Deck
Headquarters: Egypt

Estasharah pitch deck PDF

The full Estasharah deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Estasharah pitch deck was used for

This deck is a 23‑slide fundraising presentation dated November 2018 for Estasharah, a mobile‑first telehealth platform offering remote medical consultations for Egyptian patients. It illustrates a heavy emphasis on user flow from patient onboarding through consultation and follow‑up, and describes a high‑commission revenue model on medical services delivered via the platform. The timing and content suggest it was used as an early‑stage/seed‑stage pitch, shortly after the company’s founding in 2018, to raise capital for scaling its teleconsultation product in Egypt. External sources later describe an almost identically positioned platform “Estshara/Estshara” founded in 2018 by Amin El‑Hemaily and Ahmed Mahmoud that went on to raise a $500,000 seed round, but the deck itself predates that announced round.

Business model: Online telehealth platform providing remote medical consultations via web, mobile and messaging interfaces to patients in Egypt and wider MENA, with doctors offering diagnosis, treatment advice, prescriptions and follow‑up sessions.

Round: Seed (for the confirmed $500,000 round in 2021).
Lead investor: Egypt Ventures (for the 2021 Estshara seed round).
Investors: Egypt Ventures (seed round lead for Estshara in 2021), Misk Accelerator (listed as an investor in Estshara)., Flat6Labs (listed as an investor in Estshara).
Founded: 2018
Founders: Amin El‑Hemaily, Ahmed Mahmoud
Industry: Telehealth / Healthtech / Online healthcare consultations

Year: 2021 (for the confirmed Estshara seed round; the 2018 Estasharah deck predates this and its specific raise year/close are not documented externally).

Raising: The specific target amount and terms associated with the November 2018 Estasharah deck are not publicly disclosed; available external data only confirm a later $500,000 seed round in 2021 under the Estshara/Estshara brand.

Raised: $500,000 seed round announced in 2021 for Estshara/Estshara, the Cairo‑based teleconsultations platform founded in 2018 by Amin El‑Hemaily and Ahmed Mahmoud.

Headquarters: Cairo / New Cairo, Egypt (HQ listed as Maadi in Estasharah’s LinkedIn; Estshara/Estshara data points to New Cairo/Nasr City within Greater Cairo).

Total funding: At least $500,000 seed round raised by closely related brand Estshara in 2021; Estshara is described as a Cairo‑based healthtech teleconsultations platform founded in 2018 by the same named founders, with a $500,000 Seed round led by Egypt Ventures and participation from investors such as Misk Accelerator and Flat6Labs.

Use of funds as presented: Public reporting indicates that Estshara used its seed funding to scale teleconsultation services, expand its user base, and partner with providers such as Integrated Diagnostic Holding to centralize tests and 24/7 medical advice on one platform.

What happened after the Estasharah deck

While the specific outcome of the November 2018 Estasharah fundraise is not publicly documented, closely aligned data on Estshara/Estshara indicate that the founders and platform later secured a $500,000 seed round in 2021 and scaled to millions of users and hundreds of thousands of consultations, suggesting successful evolution into a prominent Egyptian telehealth provider.

Related platform Estshara/Estshara, founded in 2018 by Amin El‑Hemaily and Ahmed Mahmoud, reported serving over two mill
The same platform announced a $500,000 seed funding round in 2021 led by Egypt Ventures, alongside participation from in
Subsequent partnerships, such as integration with Integrated Diagnostic Holding’s Al Mokhtabar labs, enabled patients to

What the Estasharah deck got right

Early product vision aligned with later proven telehealth capabilities. The deck’s focus on a mobile‑first, remote consultation workflow closely matches later, externally validated product capabilities—online consultations, rapid doctor response times, and integration with telepharmacy—demonstrating strong alignment between early vision and subsequent execution.
Compelling problem and large, validated market in Egyptian telehealth. Estasharah targets a clear and significant pain point: limited, inconvenient access to doctors and healthcare advice for Egyptian patients, which external data on Estshara’s growth to millions of users and hundreds of thousands of consultations confirms as a large, receptive market.
Strong founding and product‑driven team with growth experience. External profiles highlight a co‑founding team with experience in product development and digital marketing, having grown the platform to hundreds of thousands of consultations and leading cross‑functional teams, which supports investor confidence in execution capability behind the 2018 pitch.
Strategic potential to become an integrated healthcare gateway. Later investor and market coverage describes Estshara as integrating teleconsultation with telepharmacy services and partnerships with diagnostic labs, indicating that the platform evolved into a comprehensive patient gateway—an attractive strategic direction already hinted at by the deck’s emphasis on multi‑step user flow.
Clear initial monetization with room to evolve into packages and B2B. The high‑commission revenue model presented in the deck is consistent with the platform’s ability to monetize consultations and associated services; subsequent movement toward packaged and B2B offerings demonstrates flexibility to adjust monetization while retaining the core digital health value proposition.

What could have been stronger

Lack of externally confirmed traction metrics in the 2018 deck. Because no slide text is readable from OCR and Estasharah’s own public materials are sparse, there is no externally verifiable detail in the deck about concrete metrics such as user numbers, consultation volume, revenue, or retention at the time of the 2018 raise, making it difficult for investors to gauge traction relative to later reported figures (e.g., Estshara’s 2M+ users and 200,000 consultations in 2021).
Limited visible emphasis on regulation and clinical governance. The Slideshare deck focuses heavily on user flow and a high‑commission revenue structure but, based on available external context, offers little verifiable information about regulatory compliance, data protection, or medical liability frameworks, which are critical in Egypt’s telemedicine space and would likely require substantial elaboration in investor discussions.
Brand and naming ambiguity versus later "Estshara/Estshara" presence. External profiles confirm both Estasharah (Messenger‑bot‑based) and Estshara (web and mobile platform) operating in overlapping telehealth niches in Cairo, which may raise questions about brand clarity and how the 2018 deck positioned the company’s name, domain and go‑to‑market to avoid confusion among patients and investors.

How an investor would read this deck

What draws attention

Clarify the relationship between Estasharah (as presented in the 2018 deck) and the later, more widely referenced Estshara/Estshara platform that reports significant traction and a $500,000 seed round, including whether this represents a rebrand or a distinct entity.
Understand the economics of the stated high‑commission business model in the deck, including commission rates, payer mix (patients vs. insurers/employers), and how this compares to the later package‑based pricing and telepharmacy offerings described for Estshara.
Assess competitive positioning within Egypt’s teleconsultation market, where multiple platforms (Estshara, ElBalto, Limitless Care, etc.) are active, and determine how Estasharah planned to differentiate on user experience, doctor network, or integration with labs and pharmacies.
Evaluate operational capabilities hinted at in external sources—such as 24/7 doctor availability, response time under 45 seconds, and integration with diagnostic labs—and confirm which of these were already envisioned or built at the time of the 2018 deck versus added later.

Risks that stand out

Regulatory and compliance risk is material in telemedicine, and the 2018 deck appears to under‑document how Estasharah would meet Egyptian healthcare regulations around remote consultations, prescriptions, and data privacy, which could delay scale or create legal exposure.
Brand and entity confusion between Estasharah and Estshara/Estshara may signal governance or strategy challenges and could complicate future fundraising, partnerships, or exits if not clearly resolved.
Execution risk is non‑trivial in a crowded, fast‑moving telehealth market with multiple local competitors; investors must be confident that the team’s product strategy, doctor recruitment, and integrations can sustain differentiation beyond an initial user‑flow‑led MVP.
Reliance on high commissions from medical services as a primary revenue lever may face pushback from providers and insurers and could require adaptation to subscription packages or employer/insurer contracts, as seen in later Estshara offerings, introducing business model risk.

Questions this deck invites

What legal entity and brand does the 2018 Estasharah deck correspond to today, and how did the company’s name, corporate registrations, and domains evolve in relation to Estshara/Estshara?
What exact round (pre‑seed, seed, bridge) was the November 2018 deck used for, what amount was targeted, and which investors (if any) ultimately participated, given that a $500,000 seed was announced only in 2021?
Which user and revenue metrics were current at the time of the 2018 deck, and how did they compare with later reported traction (millions of users and hundreds of thousands of consultations) to validate growth and unit economics?
How did Estasharah plan to manage clinical quality, liability, and data privacy in 2018, and what regulatory approvals or partnerships were in place in Egypt’s healthcare system?
What was Estasharah’s original technology stack and product roadmap (Messenger bot vs. native apps vs. web platform), and how did this influence acquisition costs, doctor engagement, and the viability of its high‑commission revenue structur

What founders can take from the Estasharah deck

Early telehealth pitches that rely heavily on user flow diagrams and commission‑based revenue models benefit from complementing this with clearly sourced traction metrics and unit economics; without externally verifiable numbers, investors must extrapolate from broader market data and later outcomes
Clear and consistent branding (company name, domain, product identity) is critical in healthtech markets where multiple similar platforms exist; the Estasharah/Estshara case illustrates how ambiguity between names can complicate later research and investor narrative even when the underlying service
Documenting regulatory strategy and clinical governance in a telemedicine deck is as important as product UX; investors will look for explicit plans around licensing, data protection, medical liability, and partnerships with payers and regulators.
Telehealth startups in emerging markets often evolve from consumer pay‑per‑consultation models toward packaged plans and B2B2C insurance or employer offerings; positioning this evolutionary path in the deck can help investors understand long‑term scalability beyond initial high‑commission structures
Demonstrating integration with the broader healthcare ecosystem—labs, pharmacies, and diagnostic providers—strengthens a teleconsultation pitch, as later Estshara partnerships with diagnostic groups show the value of becoming a single patient gateway.
When a later funding round is publicly announced (like Estshara’s $500,000 seed), connecting that outcome back to the narrative and strategy of earlier decks can help founders refine what resonated with investors and where documentation needed to improve.

Estasharah pitch deck: common questions

What does Estasharah do?

Estasharah is an online telehealth platform based in Cairo that lets patients find doctors in their region, communicate with them via messaging and other remote channels, and receive medical consultations and related services without visiting a clinic in person.

What is the context of Estasharah’s 2018 pitch deck?

The Slideshare pitch deck is dated November 2018 and appears to be an early fundraising presentation for Estasharah’s mobile‑first medical consultation platform targeting the Egyptian market, likely around its seed/early stage shortly after the company’s founding in 2018.

Is Estasharah a real company beyond this pitch deck?

Yes. External profiles confirm Estasharah/Estshara as a Cairo‑based telehealth startup founded in 2018 to provide online medical consultations and telepharmacy services, aligning closely with the product positioning and user flow descriptions in the November 2018 deck.

Did Estasharah successfully raise funding, and is it linked to the $500,000 seed round?

Later sources report a $500,000 seed round in 2021 for a closely related brand Estshara/Estshara, led by Egypt Ventures and including investors such as Misk Accelerator and Flat6Labs, but that funding announcement is three years after the 2018 deck and may reflect a rebranded or evolved version of the same business rather than the specific raise shown in the deck.

What problem is Estasharah trying to solve and what is its value proposition?

The deck shows a mobile‑first workflow for patients to select doctors, conduct teleconsultations, receive treatment advice or prescriptions, and store health data, combined with a high‑commission revenue model; later external descriptions highlight 24/7 consulting access, package‑based pricing, and telepharmacy services, confirming that the core value proposition is remote, accessible healthcare for Egyptian and MENA patients.